Katalog der Deutschen Nationalbibliothek

Expertensuche ?

Servicezeiten in Frankfurt am Main ab 1. Dezember 2025: Montag bis Freitag 9–18 Uhr und Samstag 10–16 Uhr
Service hours in Frankfurt am Main from 1 December 2025: Monday to Friday 9:00-18:00 and Saturday 10:00-16:00

Dienstag 9. Dezember 2025: Die Lesesäle der Deutschen Nationalbibliothek in Leipzig öffnen wegen einer Personalversammlung erst ab 13 Uhr. // Tuesday 9 December 2025: The reading rooms of the German National Library in Leipzig will open at 13:00 due to a staff assembly.

Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

51 - 60 von 77

	51	Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study Enthalten in Drug safety Bd. 42, 21.6.2019, Nr. 12, date:12.2019: 1437-1447
	52	Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC) Enthalten in BioDrugs Bd. 35, 15.7.2021, Nr. 4, date:7.2021: 417-428
	53	Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim Enthalten in Annals of hematology Bd. 103, 8.1.2024, Nr. 3, date:3.2024: 947-956
	54	Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study Enthalten in BioDrugs Bd. 38, 22.11.2023, Nr. 1, date:1.2024: 121-131
	55	Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials Enthalten in BioDrugs Bd. 34, 23.9.2020, Nr. 5, date:10.2020: 681-694
	56	Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study Enthalten in BioDrugs Bd. 35, 16.10.2021, Nr. 6, date:11.2021: 735-748
	57	Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin Enthalten in Diabetes therapy Bd. 13, 1.6.2022, Nr. 7, date:7.2022: 1299-1310
	58	Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin Enthalten in Diabetes therapy Bd. 12, 11.1.2021, Nr. 2, date:2.2021: 557-568
	59	Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial Enthalten in Scientific reports Bd. 14, 22.10.2024, Nr. 1, date:12.2024: 1-12
	60	Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis Enthalten in BMC health services research Bd. 19, 16.8.2019, Nr. 1, date:12.2019: 1-13

51 - 60 von 77

Alle Materialarten > Online Ressourcen (77)

Alle Kataloge/Sammlungen

Hochschulschriften (3)

Alle Standorte > Online (frei zugänglich) (77)

Aktionen

Administration